29 completed, 3 recruiting, 2 terminated, 2 unknown. 14 Phase 3, 10 Phase 1, 10 Phase 4, 4 Phase 2, 1 Early Phase 1.
Follow ertugliflozin: new trials by email Literature Review of ertugliflozin trials Research Report on ertugliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction Ertugliflozin 10 mg, Standard AMI Care - Type 2 Diabetes Mellitus Myocardial Infarction | Phase 4 | Not yet recruiting | Shanghai Zhongshan Hospital | 476 | 2026-07-01 | 2026-06-24 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition. Ertugliflozin/Metformin film coated tablets, Segluromet film coated tablets - Type 2 Diabetes | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2025-08-22 | 2025-12-05 |
| DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg - Diabetes Mellitus, Diabetic Kidney Disease | Phase 4 | Completed | Amsterdam UMC, location VUmc | 41 | 2023-07-03 | 2026-04-15 |
| Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers SGLT2 inhibitor, Controlled, Adaptive Study Diet - Ketones, Metabolism | Phase 1 | Active not recruiting | AdventHealth Translational Research Institute | 9 | 2023-03-16 | 2026-03-30 |
| Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD Ertugliflozin 5 mg, 15mg - Liver Fat, Liver Fibrosis | Phase 4 | Recruiting | Getz Pharma | 164 | 2023-03-01 | 2025-03-21 |
| ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF Ertugliflozin, Placebo - Heart Failure With Reduced Ejection Fraction, Congestion | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 28 | 2023-02-02 | 2026-05-11 |
| Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients SGLT2 inhibitor - Type2Diabetes | Unknown | University of Milan | 800 | 2022-09-01 | 2022-07-28 | |
| Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study Ertugliflozin 5 mg, Placebo 5mg - Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction | Phase 3 | Terminated | Medical University of Graz | 55 | 2021-06-24 | 2025-06-03 |
| Ertugliflozin in Chronic Heart Failure Ertugliflozin, Metolazone, Placebo - Heart Failure | Phase 2 | Recruiting | Yale University | 60 | 2021-03-10 | 2025-10-08 |
| Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. Ertugliflozin 15 mg - Type 2 Diabetes Mellitus, Diabetic Kidney Disease | Phase 4 | Completed | Amsterdam UMC, location VUmc | 40 | 2020-12-10 | 2023-05-01 |
| Ertugliflozin for Functional Mitral Regurgitation Ertugliflozin, Placebo - Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction | Phase 3 | Completed | Asan Medical Center | 128 | 2020-11-04 | 2025-01-06 |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE theraputic heparin, prophylactic heparin, P2Y12 - Covid19 | Phase 4 | Completed | Matthew Neal MD | 3591 | 2020-09-04 | 2024-12-30 |
| SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study SGLT2 inhibitor - Myocardial Infarction, Diabetes Mellitus, Type 2 | Recruiting | Kiyuk Chang | 1000 | 2020-08-01 | 2025-01-03 | |
| Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL) Ertugliflozin, Placebo - Heart Failure With Nonischemic Cardiomyopathy | Phase 3 | Unknown | Yonsei University | 52 | 2020-08-01 | 2020-08-07 |
| Ertugliflozin: Cardioprotective Effects on Epicardial Fat Ertugliflozin - Cardiovascular Diseases, Atherosclerosis | Early Phase 1 | Completed | Stanford University | 61 | 2020-07-01 | 2026-06-04 |
| Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Ertugliflozin 5 mg, Placebo oral tablet - Heart Failure, Diastolic, Diabetes Mellitus, Type 2 | Phase 4 | Terminated | University Hospitals Cleveland Medical Center | 9 | 2020-03-01 | 2023-12-13 |
| Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 166 | 2019-10-08 | 2025-10-31 |
| Effect of Ertugliflozin on Cardiac Function in Diabetes Ertugliflozin, Placebo - Type2 Diabetes, Heart Failure | Phase 3 | Completed | Soo Lim | 102 | 2019-06-01 | 2024-11-20 |
| Approaches To Therapy Escalation In T2D DPP-4 inhibitor, SGLT2 inhibitor, SGLT2 inhibitor and DPP-4 inhibitor - Type2 Diabetes | Phase 4 | Withdrawn | LMC Diabetes & Endocrinology Ltd. | 2019-05-01 | 2019-09-27 |
Showing 20 of 41. Sign in to see all of them.
Diabetes Mellitus, Type 2 (27) · Diabetes Mellitus (4) · Heart Failure (4) · Hypertension (3) · Cardiovascular Diseases (2) · Diabetic Nephropathies (2) · Albuminuria (1) · Atherosclerosis (1) · Body Weight Changes (1) · COVID-19 (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Glucose Metabolism Disorders (1) · Heart Failure, Diastolic (1) · Hyperkalemia (1)
Merck Sharp & Dohme LLC (20) · Amsterdam UMC, location VUmc (2) · AdventHealth Translational Research Institute (1) · Asan Medical Center (1) · Baylor Research Institute (1) · Cedars-Sinai Medical Center (1) · Getz Pharma (1) · Humanis Saglık Anonim Sirketi (1) · Icahn School of Medicine at Mount Sinai (1) · Kiyuk Chang (1) · LMC Diabetes & Endocrinology Ltd. (1) · Matthew Neal MD (1) · Medical University of Graz (1) · Shanghai Zhongshan Hospital (1) · Soo Lim (1)
United States (9) · South Korea (4) · Italy (3) · Netherlands (3) · Canada (2) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Colombia (1) · Costa Rica (1) · Dominican Republic (1) · France (1) · Guatemala (1) · Hungary (1)
Carlos G Santos-Gallego, MD (1) · David ZI Cherney, MD PhD (1) · Dirk von Lewinski, Assoc-Prof. (1) · Jeffrey Berger, MD (1) · Jeffrey Testani, MD (1) · Judith Hochman, MD (1) · Kiyuk Chang, MD, PhD (1) · Melissa Erickson, PhD (1) · Mikhail Kosiborod, MD (1) · Paolo Fiorina, MD (1) · Ronald M. Goldenberg, MD (1) · Scott Solomon, MD (1)
PMID 34213819, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 33813736, PMID 32700393, PMID 31064361, PMID 32236732, PMID 32337660, PMID 36763328, PMID 38770818, PMID 25754396, PMID 25951755, PMID 28116776, PMID 28605608, PMID 28606345, PMID 28703316, PMID 28857451, PMID 28921862, PMID 29159457, PMID 29266675, PMID 29282633, PMID 29313282, PMID 29419917, PMID 29693360, PMID 30224193, PMID 30415602, PMID 30559238, PMID 30614616, PMID 30760125, PMID 30802200, PMID 30830724, PMID 30990260, PMID 31843945, PMID 32966714, PMID 33026243, PMID 33314761, PMID 33434408, PMID 33502773, PMID 33665685, PMID 33694093, PMID 33721213, PMID 33769675, PMID 34288547, PMID 34473343, PMID 34497110, PMID 34620621, PMID 35045327
1OT2HL156812-01 (1), 2009 (1), 2014 (1), 2017 (1)